(Q43547536)

24 November 2017

Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study (English)

1 reference

24 November 2017

1 reference

C Tanislav

1

1 reference

24 November 2017

M Kaps

2

1 reference

24 November 2017

A Rolfs

3

1 reference

24 November 2017

T Böttcher

4

1 reference

24 November 2017

K Lackner

5

1 reference

24 November 2017

E Paschke

6

1 reference

24 November 2017

H Mascher

7

1 reference

24 November 2017

M Laue

8

1 reference

24 November 2017

F Blaes

9

1 reference

24 November 2017

23 September 2010

1 reference

European Journal of Neurology

24 November 2017

1 reference

24 November 2017

18

1 reference

24 November 2017

4

1 reference

24 November 2017

631-636

1 reference

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

24 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Misleading terms in Anderson-Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Functional assessment of A delta and C fibers in patients with Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Fabry disease: overall effects of agalsidase alfa treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Agalsidase alfa and kidney dysfunction in Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Etiology of small-fiber neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Detection of a characteristic painful neuropathy in Fabry disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Small-fibre involvement in diabetic patients with neuropathic foot pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Plasma globotriaosylsphingosine as a biomarker of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Determination of globotriaosylceramide in plasma and urine by mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Fabry disease. An interdisciplinary challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Fabry disease: treatment and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

High incidence of later-onset fabry disease revealed by newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Kidney transplantation in patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Skin biopsy for the diagnosis of peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03227.X

10.1111/J.1468-1331.2010.03227.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference